Herz Und Diabeteszentrum NRW Bad Oeynhausen Universitaetsklinik Der Ruhr-Universitaet Bochum

The Institute of Anesthesiology and Pain Therapy at the Herz Und Diabeteszentrum NRW is conducting studies aimed at reducing heart‑related events, lowering harmful cholesterol levels, and improving outcomes after cardiac procedures.

• Heart failure prevention
• LDL‑cholesterol lowering therapies
• Lipoprotein(a) reduction strategies
• Major adverse cardiovascular event (MACE) reduction
• Acute kidney injury risk after cardiac surgery

These trials combine advanced imaging, biomarker analysis, and patient‑reported outcomes to evaluate new therapeutic options for people at high cardiovascular risk.

Researchers are testing innovative approaches to achieve sustainable weight loss and improve metabolic health in individuals with obesity, overweight, and related conditions.

• Weight reduction interventions
• Combination therapies for obesity
• Metabolic syndrome management
• Impact on cardiovascular outcomes
• Safety of new weight‑loss agents

The program emphasizes both efficacy and quality‑of‑life improvements, targeting patients with or without type 2 diabetes.

The site is evaluating novel insulin formulations and adjunctive medicines to enhance glycemic control in type 1 diabetes and type 2 diabetes, while also addressing painful diabetic peripheral neuropathy.

• Glycemic control with novel insulins
• Pain relief for diabetic neuropathy
• Renal protection in diabetes
• Combination of SGLT2 inhibitors with other agents
• Long‑term safety of insulin analogues

Outcomes include blood‑sugar metrics, kidney function, and patient‑reported pain relief.

Studies focus on both obstructive and non‑obstructive hypertrophic cardiomyopathy, testing agents that may improve heart muscle function and patient symptoms.

• Symptom improvement
• Exercise capacity enhancement
• Cardiac imaging outcomes
• Quality‑of‑life measures
• Safety of myosin inhibitors

Researchers use imaging, functional tests, and questionnaires to assess therapeutic benefit.

Ongoing trials aim to slow progression of chronic kidney disease and prevent acute kidney injury in patients undergoing major cardiac surgery.

• Slowing CKD progression
• Preventing AKI after cardiac procedures
• Blood pressure management in CKD
• Renal outcomes with novel agents
• Biomarker monitoring for kidney health

The work integrates renal function testing with cardiovascular risk assessment to protect kidney health.

Research includes treatment of polycystic ovary syndrome and evaluation of maternal oxygen therapy to support fetal heart development in high‑risk pregnancies.

• Menstrual irregularity treatment
• Weight‑related PCOS management
• Maternal oxygen therapy for fetal heart development
• Hormonal regulation strategies
• Safety of interventions during pregnancy

These projects address both endocrine balance and fetal cardiovascular outcomes, offering new options for women of reproductive age.

A dedicated program evaluates novel agents to relieve pain associated with diabetic peripheral neuropathy, aiming to improve daily functioning and overall well‑being.

• Novel analgesic agents
• Quality‑of‑life assessments
• Safety profile evaluation
• Dose‑response studies
• Impact on daily functioning

The trials combine patient‑reported outcomes with objective pain measurements to determine therapeutic value.